- Home
- LYFT vs GH Comparison
LYFT vs GH Comparison
Compare LYFT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | GH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 13.3B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LYFT | GH |
|---|---|---|
| Price | $13.30 | $92.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 30 | 19 |
| Target Price | $20.14 | ★ $121.11 |
| AVG Volume (30 Days) | ★ 14.9M | 1.6M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | 6.74 |
| EPS | ★ 6.81 | N/A |
| Revenue | ★ $6,316,261,000.00 | $982,021,000.00 |
| Revenue This Year | $17.73 | $33.40 |
| Revenue Next Year | $12.39 | $28.32 |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | 9.16 | ★ 32.88 |
| 52 Week Low | $9.66 | $36.36 |
| 52 Week High | $25.54 | $120.74 |
Technical Indicators
Market Signals| Indicator | LYFT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 52.96 |
| Support Level | $12.97 | $89.32 |
| Resistance Level | $14.24 | $103.16 |
| Average True Range (ATR) | 0.49 | 3.90 |
| MACD | 0.08 | 0.95 |
| Stochastic Oscillator | 48.41 | 98.95 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.